Full CMC and Toxicology support in 2026
From 2026 onwards, CarboHyde will offer integrated product development and manufacturing support, including complete CMC packages and toxicology services. This expansion strengthens CarboHyde’s capacity to support partners from early discovery and formulation through regulatory-ready development.
New capability deck: Cyclodextrin expertise
A new presentation deck detailing CarboHyde’s support in cyclodextrin-based products is now available. The deck outlines our activities from initial screening to pilot production.
Ready-to-use cyclodextrin complexes for food supplements
CarboHyde will soon introduce readily available cyclodextrin complexes tailored for food supplement applications, expanding its portfolio into nutraceutical markets. We are focusing on ingredients that have a high price, yet particularly low bioavailability, thus their current use is far from economic.
3-Year Alzheimer’s drug development programme
CarboHyde is launching a three-year R&D programme focused on the development of a novel cyclodextrin-based therapeutic candidate for Alzheimer’s disease. This initiative marks a significant step towards proprietary drug innovation within the company’s core expertise.
We already have substantial animal data and validated results. This Eurostars program will focus on bringing the innovation ready to clinic via scaling, GMP production, non-GLP and GLP animal studies in the coming 3 years in collaboration with the Korean company Renatus and Ajou University.
Follow us on LinkedIn for more project updates.